In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Maverick Capital leads $39.7mm private financing for XenoPort

Executive Summary

XenoPort, which uses transporter proteins found in the GI tract to improve drug absorption, netted $39.7mm in a registered direct offering of 1.9mm shares at $21.17 each (a slight discount to the market average) to lead investor Maverick Capital as well as Venrock Healthcare Capital Partners and VCHP Co-Investment Holdings. Backers also received five-year warrants to purchase another 283k shares for $25.40 apiece.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies